Sanibel Captiva Trust Company Inc. Sells 2,635 Shares of Kenvue Inc. (NYSE:KVUE)

Sanibel Captiva Trust Company Inc. cut its position in shares of Kenvue Inc. (NYSE:KVUE) by 6.7% in the fourth quarter, HoldingsChannel reports. The firm owned 36,406 shares of the company’s stock after selling 2,635 shares during the period. Sanibel Captiva Trust Company Inc.’s holdings in Kenvue were worth $777,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in KVUE. Riverview Trust Co purchased a new stake in Kenvue in the third quarter worth about $30,000. Fortitude Family Office LLC lifted its position in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares during the period. Ashton Thomas Securities LLC bought a new position in shares of Kenvue during the third quarter valued at approximately $35,000. Versant Capital Management Inc increased its holdings in Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after buying an additional 1,441 shares during the period. Finally, Deseret Mutual Benefit Administrators raised its stake in Kenvue by 49.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after buying an additional 651 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on KVUE. Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a research note on Monday, December 9th. Jefferies Financial Group began coverage on shares of Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price target on the stock. Bank of America boosted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. JPMorgan Chase & Co. raised their target price on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Citigroup reduced their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $23.08.

Kenvue Stock Performance

NYSE KVUE opened at $21.11 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market cap of $40.46 billion, a P/E ratio of 38.37, a P/E/G ratio of 1.99 and a beta of 1.46. The stock has a 50-day moving average of $22.42 and a two-hundred day moving average of $21.69. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. Kenvue’s revenue was down .4% compared to the same quarter last year. During the same period last year, the business posted $0.31 earnings per share. As a group, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.89%. Kenvue’s dividend payout ratio is currently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.